These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
62 related articles for article (PubMed ID: 7925778)
1. Factor independence of human myeloid leukemia cell lines is associated with increased phosphorylation of the proto-oncogene Raf-1. Okuda K; Matulonis U; Salgia R; Kanakura Y; Druker B; Griffin JD Exp Hematol; 1994 Oct; 22(11):1111-7. PubMed ID: 7925778 [TBL] [Abstract][Full Text] [Related]
2. Design, Synthesis, and Anti-Leukemic Evaluation of a Series of Dianilinopyrimidines by Regulating the Ras/Raf/MEK/ERK and STAT3/c-Myc Pathways. Wang C; Wang B; Mou Y; Liu X; Chen Q; Pu W; Rao Q; Wang C; Song J; Huang Y; Yan L; Huang L; Li Y Molecules; 2024 Apr; 29(7):. PubMed ID: 38611876 [TBL] [Abstract][Full Text] [Related]
3. Acute myeloid leukemia cells polarize macrophages towards a leukemia supporting state in a Growth factor independence 1 dependent manner. Al-Matary YS; Botezatu L; Opalka B; Hönes JM; Lams RF; Thivakaran A; Schütte J; Köster R; Lennartz K; Schroeder T; Haas R; Dührsen U; Khandanpour C Haematologica; 2016 Oct; 101(10):1216-1227. PubMed ID: 27390361 [TBL] [Abstract][Full Text] [Related]
4. Normal mouse lung tissue produces a growth-inhibitory factor(s) preferential for mouse monocytic leukemia cells. Ikuta T; Honma Y; Okabe-Kado J; Kasukabe T; Hozumi M Cancer Immunol Immunother; 1989; 30(3):139-44. PubMed ID: 2480847 [TBL] [Abstract][Full Text] [Related]
5. Profiling of miRNAs and their interfering targets in peripheral blood mononuclear cells from patients with chronic myeloid leukaemia. Wu SC; Lai SW; Lu XJ; Lai HF; Chen YG; Chen PH; Ho CL; Wu YY; Chiu YL Front Oncol; 2023; 13():1173970. PubMed ID: 37476380 [TBL] [Abstract][Full Text] [Related]
6. A customized mass array panel for Limsuwanachot N; Rerkamnuaychoke B; Niparuck P; Singdong R; Kongruang A; Hirunpatrawong P; Siriyakorn T; Yenchitsomanus PT; Siriboonpiputtana T J Mass Spectrom Adv Clin Lab; 2023 Apr; 28():122-132. PubMed ID: 37128502 [TBL] [Abstract][Full Text] [Related]
7. Combination Therapies in Chronic Myeloid Leukemia for Potential Treatment-Free Remission: Focus on Leukemia Stem Cells and Immune Modulation. Mu H; Zhu X; Jia H; Zhou L; Liu H Front Oncol; 2021; 11():643382. PubMed ID: 34055612 [TBL] [Abstract][Full Text] [Related]
8. Current status and novel strategy of CML. Morita K; Sasaki K Int J Hematol; 2021 May; 113(5):624-631. PubMed ID: 33782818 [TBL] [Abstract][Full Text] [Related]
9. Validation of a Outa AA; Abubaker D; Bazarbachi A; Sabban ME; Shirinian M; Nasr R Haematologica; 2020; 105(2):387-397. PubMed ID: 31101753 [TBL] [Abstract][Full Text] [Related]
10. Investigating critical genes and gene interaction networks that mediate cyclophosphamide sensitivity in chronic myelogenous leukemia. He X; Deng Y; Yue W Mol Med Rep; 2017 Jul; 16(1):523-532. PubMed ID: 28560425 [TBL] [Abstract][Full Text] [Related]
11. The Cancer Drug Dasatinib Increases PGC-1α in Adipose Tissue but Has Adverse Effects on Glucose Tolerance in Obese Mice. Sylow L; Long JZ; Lokurkar IA; Zeng X; Richter EA; Spiegelman BM Endocrinology; 2016 Nov; 157(11):4184-4191. PubMed ID: 27589085 [TBL] [Abstract][Full Text] [Related]
12. Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome. Iurlo A; Nobili A; Latagliata R; Bucelli C; Castagnetti F; Breccia M; Abruzzese E; Cattaneo D; Fava C; Ferrero D; Gozzini A; Bonifacio M; Tiribelli M; Pregno P; Stagno F; Vigneri P; Annunziata M; Cavazzini F; Binotto G; Mansueto G; Russo S; Falzetti F; Montefusco E; Gugliotta G; Storti S; D'Addosio AM; Scaffidi L; Cortesi L; Cedrone M; Rossi AR; Avanzini P; Mauro E; Spadea A; Celesti F; Giglio G; Isidori A; Crugnola M; Calistri E; Sorà F; Rege-Cambrin G; Sica S; Luciano L; Galimberti S; Orlandi EM; Bocchia M; Tettamanti M; Alimena G; Saglio G; Rosti G; Mannucci PM; Cortelezzi A Oncotarget; 2016 Nov; 7(48):80083-80090. PubMed ID: 27579540 [TBL] [Abstract][Full Text] [Related]
13. Effects of first- and second-generation tyrosine kinase inhibitor therapy on glucose and lipid metabolism in chronic myeloid leukemia patients: a real clinical problem? Iurlo A; Orsi E; Cattaneo D; Resi V; Bucelli C; Orofino N; Sciumè M; Elena C; Grancini V; Consonni D; Orlandi EM; Cortelezzi A Oncotarget; 2015 Oct; 6(32):33944-51. PubMed ID: 26376678 [TBL] [Abstract][Full Text] [Related]
14. Selecting the best frontline treatment in chronic myeloid leukemia. Yilmaz M; Abaza Y; Jabbour E Curr Hematol Malig Rep; 2015 Jun; 10(2):145-57. PubMed ID: 25921387 [TBL] [Abstract][Full Text] [Related]
15. Targeted therapies in hematology and their impact on patient care: chronic and acute myeloid leukemia. Jabbour E; Cortes J; Ravandi F; O'Brien S; Kantarjian H Semin Hematol; 2013 Oct; 50(4):271-83. PubMed ID: 24246694 [TBL] [Abstract][Full Text] [Related]
16. Outcome of treatment of chronic myeloid leukemia with second-generation tyrosine kinase inhibitors after imatinib failure. Cornelison AM; Kantarjian H; Cortes J; Jabbour E Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1(0 1):S101-10. PubMed ID: 22035738 [TBL] [Abstract][Full Text] [Related]
17. Repetitive busulfan administration after hematopoietic stem cell gene therapy associated with a dominant HDAC7 clone in a nonhuman primate. Xie J; Larochelle A; Maric I; Faulhaber M; Donahue RE; Dunbar CE Hum Gene Ther; 2010 Jun; 21(6):695-703. PubMed ID: 20102258 [TBL] [Abstract][Full Text] [Related]